Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.

RATIONALE Mycobacterium massiliense has been recognized as a separate species from Mycobacterium abscessus; however, little is known regarding the clinical impact of this differentiation. OBJECTIVES To compare clinical features and treatment outcomes between patients with M. abscessus lung disease and those with M. massiliense lung disease. METHODS We performed molecular identification of stored clinical isolates of M. abscessus complex and compared clinical characteristics and treatment outcomes between 64 patients with M. abscessus lung disease and 81 patients with M. massiliense lung disease. MEASUREMENTS AND MAIN RESULTS The clinical and radiographic manifestations of disease caused by each species were similar. Standardized combination antibiotic therapy, including a clarithromycin-containing regimen in combination with an initial 4-week course of cefoxitin and amikacin, was given to 57 patients (24 with M. abscessus and 33 with M. massiliense) for more than 12 months. The proportion of patients with sputum conversion and maintenance of negative sputum cultures was higher in patients with M. massiliense infection (88%) than in those with M. abscessus infection (25%; P < 0.001). Inducible resistance to clarithromycin (minimal inhibitory concentrations ≥ 32 μg/ml) was found in all tested M. abscessus isolates (n = 19), but in none of the M. massiliense isolates (n = 28). CONCLUSIONS Treatment response rates to combination antibiotic therapy including clarithromycin were much higher in patients with M. massiliense lung disease than in those with M. abscessus lung disease. The inducible resistance to clarithromycin could explain the lack of efficacy of clarithromycin-containing antibiotic therapy against M. abscessus lung disease.

[1]  Young Kil Park,et al.  Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.

[2]  W. Gill,et al.  Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages , 2007, Scandinavian journal of infectious diseases.

[3]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[4]  Young Kil Park,et al.  Evaluation of the Broth Microdilution Method Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride for Rapidly Growing Mycobacteria Susceptibility Testing , 2007, Journal of Korean medical science.

[5]  S. Conlan,et al.  Cohort Study of Molecular Identification and Typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii , 2009, Journal of Clinical Microbiology.

[6]  E. Picard,et al.  Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel , 2008, Emerging infectious diseases.

[7]  J. Gaillard,et al.  Multicenter Study of Prevalence of Nontuberculous Mycobacteria in Patients with Cystic Fibrosis in France , 2009, Journal of Clinical Microbiology.

[8]  C. Welinder-Olsson,et al.  Molecular Epidemiology of Mycobacterium abscessus, with Focus on Cystic Fibrosis , 2007, Journal of Clinical Microbiology.

[9]  Y. Kook,et al.  Outbreak of Mycobacterium massiliense Infection Associated with Intramuscular Injections , 2007, Journal of Clinical Microbiology.

[10]  Ji‐Hyun Lee,et al.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[11]  Young Kil Park,et al.  Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. , 2006, Chest.

[12]  R. Wallace,,et al.  A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2008, Antimicrobial Agents and Chemotherapy.

[13]  D. van Soolingen,et al.  Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. , 2009, The Journal of infection.

[14]  Young Kil Park,et al.  Clinical Significance Of Differentiation Between Mycobacterium Abscessus And Mycobacterium Massiliense , 2010, ATS 2010.

[15]  C. Petti,et al.  Identification of an Emerging Pathogen, Mycobacterium massiliense, by rpoB Sequencing of Clinical Isolates Collected in the United States , 2007, Journal of Clinical Microbiology.

[16]  K. Olivier,et al.  Diagnosis and treatment of infections caused by rapidly growing mycobacteria. , 2008, Seminars in respiratory and critical care medicine.

[17]  R. Good,et al.  Spectrum of disease due to rapidly growing mycobacteria. , 1983, Reviews of infectious diseases.

[18]  K. Lee,et al.  Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective , 2005, Journal of Korean medical science.

[19]  R. Wallace,,et al.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. , 1990, The American review of respiratory disease.

[20]  Young Kil Park,et al.  In Vitro Antimicrobial Susceptibility of Mycobacterium abscessus in Korea , 2008, Journal of Korean medical science.

[21]  S. Wann,et al.  Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002. , 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  E. Tortoli,et al.  Characterization of Mycobacteria from a Major Brazilian Outbreak Suggests that Revision of the Taxonomic Status of Members of the Mycobacterium chelonae-M. abscessus Group Is Needed , 2009, Journal of Clinical Microbiology.

[23]  Gilbert Greub,et al.  Amoebal Coculture of “Mycobacterium massiliense” sp. nov. from the Sputum of a Patient with Hemoptoic Pneumonia , 2004, Journal of Clinical Microbiology.

[24]  R. Wallace,,et al.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. , 1993, The American review of respiratory disease.

[25]  R. Baughman Cytomegalovirus: the monster in the closet? , 1997, American journal of respiratory and critical care medicine.

[26]  C. Daley,et al.  Pulmonary disease caused by rapidly growing mycobacteria. , 2002, Clinics in chest medicine.

[27]  C. Ki,et al.  Report of a Korean Patient with Cystic Fibrosis, Carrying Q98R and Q220X Mutations in the CFTR Gene , 2006, Journal of Korean medical science.

[28]  N. Khardori Rapidly Growing Mycobacteria: Clinical and Microbiologic Studies of 115 Cases , 2008 .

[29]  Y. Kook,et al.  Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns , 2010, Microbiology and immunology.

[30]  T Ezaki,et al.  Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. , 1992, International journal of systematic bacteriology.

[31]  Young Kil Park,et al.  Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans , 2008, Journal of clinical laboratory analysis.

[32]  Didier Raoult,et al.  rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. , 2006, International journal of systematic and evolutionary microbiology.

[33]  R. Wallace,,et al.  Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. , 2005, The Journal of antimicrobial chemotherapy.

[34]  T. Shim,et al.  Proportions of Mycobacterium massiliense and Mycobacterium bolletii Strains among Korean Mycobacterium chelonae-Mycobacterium abscessus Group Isolates , 2008, Journal of Clinical Microbiology.

[35]  Y. Yamashiro,et al.  The estimated incidence of cystic fibrosis in Japan. , 1997, Journal of pediatric gastroenterology and nutrition.